Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP + toxicity

Experimental Neurology

Volumn 263, Issue , 2015, Pages 1-7

  Broom, Lauren ^a   Jenner, Peter ^a   Rose, Sarah ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

GDNF; Inflammation; Osteopontin; Parkinson's disease; Rat primary cultures

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 15 MER ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; ECTODYSPLASIN A; GLIAL FIBRILLARY ACIDIC PROTEIN; INTEGRIN RECEPTOR; MEMBRANE PROTEIN; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; NEUTRALIZING ANTIBODY; OSTEOPONTIN; OXYCOCIN 42; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTIC ACID; NERVE GROWTH FACTOR; NEUROTOXIN; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL COUNT; CELL CULTURE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; FEMALE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MESENCEPHALON; MICROGLIA; NEUROPROTECTION; NONHUMAN; PROTEIN DOMAIN; RAT; TISSUE CULTURE; TOXICITY TESTING; VENTRAL MESENCEPHALON; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIA; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; PARKINSONISM; WISTAR RAT;

ANIMALS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NERVE GROWTH FACTORS; NEUROGLIA; NEURONS; NEUROTOXINS; OLIGOPEPTIDES; OSTEOPONTIN; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR;

EID: 84907932860     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.09.005     Document Type: Article

References (38)

1. Ailane S., Long P., Jenner P., Rose S. Expression of integrin and CD44 receptors recognizing osteopontin in the normal and LPS-lesioned rat substantia nigra. Eur. J. Neurosci. 2013, 38:2468-2476.
2. Airaksinen M.S., Titievsky A., Saarma M. GDNF family neurotrophic factor signaling: four masters, one servant?. Mol. Cell. Neurosci. 1999, 13:313-325.
3. Arafat H.A., Katakam A.K., Chipitsyna G., Gong Q., Vancha A.R., Gabbeta J., Dafoe D.C. Osteopontin protects the islets and beta-cells from interleukin-1 beta-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology 2007, 148:575-584.
4. Arenas E., Trupp M., Åkerud P., Ibáñez C.F. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 1995, 15:1465-1473.
5. Asami T., Ito T., Fukumitsu H., Nomoto H., Furukawa Y., Furukawa S. Autocrine activation of cultured macrophages by brain-derived neurotrophic factor. Biochem. Biophys. Res. Commun. 2006, 344:941-947.
6. Attur M.G., Dave M.N., Clancy R.M., Patel I.R., Abramson S.B., Amin A.R. Functional genomic analysis in arthritis-affected cartilage: yin-yang regulation of inflammatory mediators by alpha 5-beta 1 and alpha V beta 3 integrins. J. Immunol. 2000, 164:2684-2691.
7. Baliga S.S., Merrill G.F., Shinohara M.L., Denhardt D.T. Osteopontin expression during early cerebral ischemia-reperfusion in rats: enhanced expression in the right cortex is suppressed by acetaminophen. PLoS ONE 2011, 6(1):e14568. (Doi:10.137).
8. Bill H.M., Knudsen B., Moores S.L., Muthuswamy S.K., Rao V.R., Brugge J.S., Miranti C.K. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol. Cell. Biol. 2004, 24:8586-8599.
9. Brown A. Osteopontin: a key link between immunity, inflammation and the central nervous system. Transl. Neurosci. 2012, 3(3):288-293.
10. Caers J., Gunthert U., Raeve H., Valckenborgh E.V., Menu E., Riet I.V., Camp B.V., Vanderkerken K. The involvement of OPN and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br. J. Haematol. 2006, 132:469-477.
11. Chao C.C., Ma Y.L., Chu K.Y., Lee E.H. Integrin alpha V and NCAM mediate the effects of GDNF on DA neuron survival, outgrowth, DA turnover and motor activity in rats. Neurobiol. Aging 2003, 24:105-116.
12. Du Y., Ma Z., Lin S., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. 2001, 98:14669-14674.
13. Du F., Li R., Huang Y., Li X., Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 2005, 22:2422-2430.
14. Ellison J.A., Barone F.C., Feuerstein G.Z. Matrix remodeling after stroke: de novo expression of matrix proteins and integrin receptors. Ann. N. Y. Acad. Sci. 1999, 890:204-222.
15. Gall C.M., Pinkstaff J.K., Lauterborn J.C., Xie Y., Lynch G. Integrins regulate neuronal neurotrophin gene expression through effects on voltage-sensitive calcium channels. Neuroscience 2003, 118:925-940.
16. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
17. Granholm A.-C., Reyland M., Albeck D., Sanders L., Gerhardt G., Hoernig G., Shen L., Westphal H., Hoffer B. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J. Neurosci. 2000, 20:3182-3190.
18. Heilmann K., Hoffmann U., Witte E., et al. Osteopontin as two-sided mediator of intestinal inflammation. J. Cell. Mol. Med. 2009, 13:1162-1174.
19. Hu D.D., Lin E.C.K., Kovach N.L., Hoyer J.R., Smith J.W. A biochemical characterization of the binding of osteopontin to integrins alpha V-beta 1 and alpha V-beta 5. J. Biol. Chem. 1995, 270:26232-26238.
20. Huang C., Ma R., Sun S., Wei G., Fang Y., Liu R., Li G. JAK2- STAT3 signaling pathway mediates thrombin-induced proinflammatory actions of microglia in vitro. J. Neuroimmunol. 2008, 204:118-125.
21. Iczkiewicz J., Rose S., Jenner P. Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Res. Mol. Brain Res. 2004, 132:64-72.
22. Iczkiewicz J., Jackson M.J., Smith L.A., Rose S., Jenner P. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res. 2006, 1118:239-250.
23. Iczkiewicz J., Rose S., Jenner P. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Exp. Neurol. 2007, 207:95-106.
24. Iczkiewicz J., Broom L., Cooper J.D., Wong A.M.S., Rose S., Jenner P. The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. J. Neurochem. 2010, 114:1792-1804.
25. Irita J., Okura T., Jotoku M., et al. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am. J. Physiol. Ren. Physiol. 2011, 301:F833-F844.
26. Iwakura Y., Zheng Y., Sibilia M., et al. Qualitative and quantitative reevaluation of epidermal growth factor-ErbB1 action on developing midbrain dopaminergic neurons in vivo and in vitro: target-derived neurotrophic signaling (Part 1). J. Neurochem. 2011, 118:45-56.
27. Katakam A.K., Chipitsyna G., Gong Q., Vancha A.R., Gabbeta J., Arafat H.A. Streptozotocin (STZ) mediates acute upregulation of serum and pancreatic osteopontin (OPN): a novel islet-protective effect of OPN through inhibition of STZ-induced nitric oxide production. J. Endocrinol. 2005, 187:237-247.
28. Khan S.A., Lopez-Chua C.A., Zhang J., Fisher L.W., Sorensen E.S., Denhardt D.T. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J. Cell. Biochem. 2002, 85:728-736.
29. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 2000, 16:724-739.
30. Knott C., Stern G., Kingsbury A., Welcher A.A., Wilkin G.P. Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra. Parkinsonism Relat. Disord. 2002, 8:329-341.
31. Lee M.Y., Shin S.L., Choi Y.S., Kim E.J., Cha J.H., Chun M.H., Lee S.B., Kim S.Y. Transient upregulation of osteopontin mRNA in hippocampus and striatum following global forebrain ischemia in rats. Neurosci. Lett. 1999, 271:81-84.
32. Maetzler W., Berg D., Schalamberidze N., Melms A., Schott K., Mueller J.C., Liaw L., Gasser T., Nitsch C. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol. Dis. 2007, 25:473-482.
33. O'Brien K.D., Kuusisto J., Reichenbach D.D., Ferguson M., Giachelli C., Alpers C.E., Otto C.M. Osteopontin Is expressed in human aortic valvular lesions. Circulation 1995, 92:2163-2168.
34. Oo T.F., Kholodilov N., Burke R.E. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J. Neurosci. 2003, 23:5141-5148.
35. O'Regan A.W., Chupp G.L., Lowry J.A., Goetschkes M., Mulligan N., Berman J.S. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J. Immunol. 1999, 162:1024-1031.
36. Scatena M., Almeida M., Chaisson M.L., Fausto N., Nicosia R.F., Giachelli C.M. NF-kappa B mediates alpha V beta 3 integrin-induced endothelial cell survival. J. Cell Biol. 1998, 141:1083-1093.
37. Staniszewska I., Sariyer I.K., Lecht S., Brown M.C., Walsh E.M., Tuszynski G.P., Safak M., Lazarovici P., Marcinkiewicz C. Integrin alpha 9-beta 1 is a receptor for nerve growth factor and other neurotrophins. J. Cell Sci. 2008, 121:504-513.
38. Wang X., Louden C., Yue T.L., Ellison J.A., Barone F.C., Solleveld H.A., Feuerstein G.Z. Delayed expression of osteopontin after focal stroke in the rat. J. Neurosci. 1998, 18:2075-2083.